Risk of Fetal Exposure to Tricyclic Antidepressants

Journal of Obstetrics and Gynaecology Canada

Volumn 26, Issue 10, 2004, Pages 887-892

  Wen, Shi Wu ^a,b   Walker, Mark ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Abnormalities; Antidepressive agents; Drug; Drug effects; Fetus; Prescriptions; Tricyclic pregnancy

Indexed keywords

TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; ARTICLE; CANADA; CLINICAL TRIAL; CONGENITAL MALFORMATION; DEPRESSION; FEMALE; FETOMATERNAL TRANSFUSION; HUMAN; META ANALYSIS; PREGNANCY; PRENATAL EXPOSURE; PRESCRIPTION; RISK FACTOR; STATISTICS;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSION; FEMALE; HUMANS; MATERNAL-FETAL EXCHANGE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PRESCRIPTIONS, DRUG; RISK FACTORS; SASKATCHEWAN;

EID: 16644400602     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)30139-6     Document Type: Article

References (43)

1. Burke KC, Burke JD, Rae DS, Regier DA Comparing age at onset of major depression and other psychiatric disorders by birth cohorts in five US community populations. Arch Gen Psychiatry 1991, 48:789-795.
2. Kuller JA, Katz VL, McMahon MJ, Wells SR, Bashford RA Pharmacologic treatment of psychiatric disease in pregnancy and lactation: fetal and neonatal effects. Obstet Gynecol 1996, 87:789-794.
3. Gupta S, Masand PS, Rangwani S. Selective serotonin reuptake inhibitors in pregnancy and lactation. Obstet Gynecol Surv 1998, 53:733-736.
4. O'Hara MW, Neunaber DJ, Zekoski EM. Prospective study of postpartum depression: prevalence, course, and predictive factors. J Abnorm Psychol 1984, 93:158-171.
5. Wen SW, Walker M The use of selective serotonin reuptake inhibitors in pregnancy. J Obstet Gynaecol Can 2004, 26(9):819-822.
6. Wisner KL, Gelenberg AJ, Leonard H, Zarin D, Frank E Pharmacologic treatment of depression during pregnancy. JAMA 1999, 282:1264-1269.
7. Hardman J, Limbird L Goodman and Gilman's: the pharmacological basis of therapeutics 1996, 445-446. McGraw Hill, New York.
8. Voirol P, Robert PA, Meister P, Oros L, Baumann P. Psychotropic drug prescription in a psychiatric university hospital. Pharmacopsychiatry 1999, 32:29-37.
9. Mamdani MM, Parikh SV, Austin PC, Upshur RE. Use of antidepressants among elderly subjects: trends and contributing factors. Am J Psychiatry 2000, 157:360-367.
10. Stahl SM Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. J Clin Psychiatry 1998, 59(l8):23-29.
11. Flint A. Choosing appropriate antidepressant therapy in the elderly. Drugs Aging 1998, 13:269-280.
12. Kaplan H, Sadock B Pocket handbook of psychiatric drug treatment 1993, Williams andWilkins, Baltimore (MD).
13. Richelson E. Pharmacology of antidepressants: characteristics of the ideal drug. Mayo Clin Proc 1994, 69:1069-1081.
14. Barron WM, Lindheimer MD Preface and guidelines for prescribing drugs to pregnant women. Medical disorders during pregnancy 1991, ix-xii. Mosby-Year Book, Inc., St. Louis (MO). W.M. Barron, M.D. Lindheimer (Eds.).
15. Robert E Treating depression in pregnancy. N Engl J Med 1996, 335:1056-1058.
16. Marx J. Do antidepressants promote tumors?. Science 1992, 257:22-23.
17. Miller LG Antidepressants and cancer: cause for concern?. J Clin Psychopharm 1993, 13:1-2.
18. Steingart AB, Cotterchio M. Do antidepressants cause, promote, or inhibit cancers?. J Clin Epidemiol 1995, 48:1407-1412.
19. Schaik N, Graf U Genotoxicity evaluation of five tricyclic antidepressants in the wing somatic mutation and recombination test in Drosophila melanogaster. Mutat Res 1991, 260:99-104.
20. Van Schaik N, Graf U. Structure activity relationships of tricyclic antidepressants and related compounds in the wing somatic mutation and recombination test of Drosophila melanogaster. Mutat Res 1993, 286:155-163.
21. Budavari S, O'Neil MJ, Smith A, Heckelman PE The Merck index. An encyclopedia of chemicals, drugs, and biologicals, 1 Ith ed 1989, Merck & Co., Rahway (NJ).
22. Chao LY, Huff V, Tomlison G, Riccardi VM, Strong LC, Saunders GF Genetic mosaicism in normal tissues ofWilms' tumour patients. Nature Genet 1993, 3:127-131.
23. Mohrenweiser H, Zingg B. Mosaicism: the embryo as a target for induction of mutations leading to cancer and genetic disease. Environ Mol Mutagen 1995, 25(26):2l-29.
24. Narod SA, Hawkins MM, Robertson CM, Stiller CA. Congenital anomalies and childhood cancer in Great Britain. Am J Hum Genet 1997, 60:474-485.
25. Hook EB Human teratogenic and mutagenic markers in monitoring about point sources of pollution. Environ Res 1981, 25:178-203.
26. Wright SC, Zhong J, Larrick JW. Inhibition of apoptosis as a mechanism of tumor promotion. FASEB J 1994, 8:654-660.
27. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996, 153:592-606.
28. Pastuszak A, Scick-Boschetto B, Zuber C, Vial T, Bellemin B, Mastroiacoro P Pregnancy outcome following first-trimester exposure to fluoxetine. JAMA 1993, 269:2246-2248.
29. McElhatton PR, Garbis HM, Elefant E, Feldkamp M, Pinelli M, Sihn S The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants: a collaborative study of the European Network of Teratology Information Services. Reprod Toxicol 1996, 10:285-294.
30. Nulman I, Rovet J, Stewart DE, Wolpin J, Gardrer HA, Theis JG Neurodevelopment of children exposed in utero to antidepressant drugs. New Engl J Med 1997, 336:258-262.
31. Ericson A, Kallen B.Wiholm B-E. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999, 55:503-508.
32. Bracken MB, Holford TR Exposure to prescribed drugs in pregnancy and association with congenital malformations. Obstet Gynecol 1981, 58:336-344.
33. Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, Hanley J. Population-based case-control study of the effects of antidepressant drugs on breast cancer risk. Br J Cancer 2002, 86:92-97.
34. Downey W, Beck P, McNutt M, Stang MR, Osei W, Nichol J. Health databases in Saskatchewan. Pharmacoepidemiology 2000, 325-345. John Wiley & Sons Ltd, Chichester (England). B.L. Strom (Ed.).
35. Miller RW How environmental hazards in childhood have been discovered: carcinogens, teratogens, neurotoxicants, and others. Pediatrics 2004, II(3):945-951.
36. Briggs GG, Freeman RK, Yaffe SJ Drugs in pregnancy and lactation 2002, Lippincott Williams &Wilkins, Philadelphia (PA).
37. Honein MA, Paulozzi LJ, Cragan JD, Correa A Evaluation of selected characteristics of pregnancy drug registries. Teratology 1999, 60:356-364.
38. Pastuszak A, Koren G, Milich V Prospective assessment of pregnancy outcome following first-trimester exposure to benzodiazepines. Maternal and fetal toxicology 1994, 77-88. Marcel Dekker, New York. G. Koren (Ed.).
39. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci 2001, 26:44-48.
40. Czeizel AE. Recommendation to avoid all drugs during first trimester is unrealistic. BMJ 1996, 313:424-425.
41. Orr ST, James SA, Blackmore Prince C Maternal prenatal depressive symptoms and spontaneous preterm births among African-American women in Baltimore, Maryland. Am J Epidemiol 2002, 156:797-802.
42. Henderson J J, Evans SF, Straton JA, Priest SR, Hagan R. Impact of postnatal depression on breastfeeding duration. Birth 2003, 30:175-180.
43. Berg LT, Feenstra N, Sorensen HT, Cornel MC Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy. Teratology 1999, 60:33-36.